EVO · Evotec SE

Evotec SE announced two significant developments on April 7, 2026, concerning corporate governance and portfolio monetization. The Supervisory Board has nominated Dieter Weinand, M.S., to succeed Prof. Dr. Iris Löw-Friedrich as Chairman of the Supervisory Board. The election is proposed for the Annual General Meeting on June 11, 2026. Weinand brings more than 30 years of global pharmaceutical industry leadership experience, having served as a member of the Board of Management of Bayer AG and President, CEO, and Chairman of the Board of Bayer Pharmaceuticals AG. His previous roles also include leadership positions at Pfizer, Bristol Myers Squibb, and Sanofi. CEO Dr. Christian Wojczewski highlighted Weinand’s deep commercial expertise and track record in strategic partnerships as instrumental for Evotec’s transformation toward sustainable profitability.

Concurrently, Evotec announced it expects to receive approximately $100 million in upfront consideration from the sale of Tubulis GmbH to Gilead Sciences. Evotec holds a 3.14% equity stake in Tubulis, acquired through Series B financing rounds in 2022 and 2024. In addition to the upfront payment, Evotec is eligible for up to approximately $58 million in contingent consideration based on specified milestones. The transaction, expected to close in Q2 2026, marks the fourth successful monetization of assets from Evotec’s investment portfolio, reflecting the company's disciplined approach to value realization. The proceeds support Evotec’s strategic focus on enhancing the value of its scientific platform and strengthening collaborations.